Teva gets (non)response from FDA on Copaxone
Executive Summary
Teva's petition requesting that ANDAs for its multiple sclerosis treatment Copaxone (glatiramer) should contain clinical data has been nominally rejected by FDA. 1FDA's denial is made "without comment on the approvability" of any application "because it would be premature and inappropriate to do so at this time." The response appears to be part of the agency's new strategy of answering petitions within the 180-day congressional deadline but not reaching a definitive conclusion on the questions because applications may still be undergoing review. The denials have frustrated firms, which are left with the choice of suing the agency or repetitioning, but FDA thinks the approach is "pretty clever" (2"The Pink Sheet," March 2, 2009, p. 29)
You may also be interested in...
Citizen Petition Changes In FDAAA Force Firms To Reconsider Timing Strategy
Legislative changes to the citizen petition process are forcing would-be petitioners to reevaluate when they should submit their petitions to the FDA
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.